Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/31938
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorDORNA, Mayra B.
dc.contributor.authorBARBOSA, Pamela F. A.
dc.contributor.authorRANGEL-SANTOS, Andreia
dc.contributor.authorCSOMOS, Krisztian
dc.contributor.authorUJHAZI, Boglarka
dc.contributor.authorDASSO, Joseph F.
dc.contributor.authorTHWAITES, Daniel
dc.contributor.authorBOYES, Joan
dc.contributor.authorSAVIC, Sinisa
dc.contributor.authorWALTER, Jolan E.
dc.date.accessioned2019-05-30T13:45:50Z
dc.date.available2019-05-30T13:45:50Z
dc.date.issued2019
dc.identifier.citationFRONTIERS IN PEDIATRICS, v.7, article ID 122, 6p, 2019
dc.identifier.issn2296-2360
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/31938
dc.description.abstractProteins expressed by recombination activating genes 1 and 2 (RAG1/2) are essential in the process of V(D)J recombination that leads to generation of the T and B cell repertoires. Clinical and immunological phenotypes of patients with RAG deficiencies correlate well to the degree of impaired RAG activity and this has been expanding to variants of combined immunodeficiency (CID) or even milder antibody deficiency syndromes. Pathogenic variants that severely impair recombinase activity of RAG1/2 determine a severe combined immunodeficiency (SCID) phenotype, whereas hypomorphic variants result in leaky (partial) SCID and other immunodeficiencies. We report a patient with novel pathogenic compound heterozygous RAG2 variants that result in a CID phenotype with two distinctive characteristics: late-onset progressive hypogammaglobulinemia and highly elevated B cell count. In addition, the patient had early onset of infections, T cell lymphopenia and expansion of lymphocytes after exposure to herpes family viruses. This case highlights the importance of considering pathogenic RAG variants among patients with preserved B cell count and CID phenotype.eng
dc.description.sponsorshipNational Institute of Allergy and Infectious Diseases, National Institutes of Health [5K08AI103035, R01 AI100887-05]
dc.description.sponsorshipJeffrey Modell Foundation
dc.description.sponsorshipRobert A. Good Endowment at the University of South Florida
dc.language.isoeng
dc.publisherFRONTIERS MEDIA SAeng
dc.relation.ispartofFrontiers in Pediatrics
dc.rightsopenAccesseng
dc.subjectRAG deficiencyeng
dc.subjectRAG2eng
dc.subjectcombined immunodeficiencyeng
dc.subjectprimary immunodeficiencyeng
dc.subjecthypomorphic varianteng
dc.subjectcompound heterozygous varianteng
dc.subject.othergranulomatous-diseaseeng
dc.subject.othermutationseng
dc.subject.otherautoimmunityeng
dc.titleCombined Immunodeficiency With Late-Onset Progressive Hypogammaglobulinemia and Normal B Cell Count in a Patient With RAG2 Deficiencyeng
dc.typearticleeng
dc.rights.holderCopyright FRONTIERS MEDIA SAeng
dc.identifier.doi10.3389/fped.2019.00122
dc.identifier.pmid31058115
dc.subject.wosPediatricseng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalCSOMOS, Krisztian:Univ S Florida, Morsani Coll Med, Dept Pediat, Div Allergy & Immunol, Tampa, FL 33620 USA
hcfmusp.author.externalUJHAZI, Boglarka:Univ S Florida, Morsani Coll Med, Dept Pediat, Div Allergy & Immunol, Tampa, FL 33620 USA
hcfmusp.author.externalDASSO, Joseph F.:Univ S Florida, Morsani Coll Med, Dept Pediat, Div Allergy & Immunol, Tampa, FL 33620 USA; Univ Tampa, Dept Biol, Tampa, FL 33606 USA
hcfmusp.author.externalTHWAITES, Daniel:Univ Leeds, Sch Mol & Cellular Biol, Leeds, W Yorkshire, England
hcfmusp.author.externalBOYES, Joan:Univ Leeds, Sch Mol & Cellular Biol, Leeds, W Yorkshire, England
hcfmusp.author.externalSAVIC, Sinisa:St James Univ Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Dept Clin Immunol & Allergy, Leeds, W Yorkshire, England
hcfmusp.author.externalWALTER, Jolan E.:Univ S Florida, Morsani Coll Med, Dept Pediat, Div Allergy & Immunol, Tampa, FL 33620 USA; Johns Hopkins All Childrens Hosp, St Petersburg, FL 33701 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA
hcfmusp.description.articlenumber122
hcfmusp.description.volume7
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000465070800001
hcfmusp.origem.id2-s2.0-85065317060
hcfmusp.publisher.cityLAUSANNEeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAbolhassani H, 2014, J ALLERGY CLIN IMMUN, V134, P1375, DOI 10.1016/j.jaci.2014.04.042eng
hcfmusp.relation.referenceBuchbinder D, 2015, J CLIN IMMUNOL, V35, P119, DOI 10.1007/s10875-014-0121-5eng
hcfmusp.relation.referenceCoussens MA, 2013, CELL REP, V4, P870, DOI 10.1016/j.celrep.2013.07.041eng
hcfmusp.relation.referenceDe Ravin SS, 2010, BLOOD, V116, P1263, DOI 10.1182/blood-2010-02-267583eng
hcfmusp.relation.referencede Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178eng
hcfmusp.relation.referenceEhl S, 2005, J CLIN INVEST, V115, P3140, DOI 10.1172/JCI25221eng
hcfmusp.relation.referenceGeier CB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133220eng
hcfmusp.relation.referenceGoda V, 2018, J ALLER CL IMM-PRACT, V6, P1769, DOI 10.1016/j.jaip.2018.01.015eng
hcfmusp.relation.referenceHenrickson SE, 2018, J CLIN IMMUNOL, V38, P642, DOI 10.1007/s10875-018-0538-3eng
hcfmusp.relation.referenceJohn T, 2016, J CLIN IMMUNOL, V36, P725, DOI 10.1007/s10875-016-0326-xeng
hcfmusp.relation.referenceKuehn HS, 2016, NEW ENGL J MED, V374, P1032, DOI 10.1056/NEJMoa1512234eng
hcfmusp.relation.referenceKuijpers TW, 2011, BLOOD, V117, P5892, DOI 10.1182/blood-2011-01-329052eng
hcfmusp.relation.referenceLawless D, 2018, J ALLERGY CLIN IMMUN, V141, P2303, DOI 10.1016/j.jaci.2018.02.007eng
hcfmusp.relation.referenceLee YN, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah6109eng
hcfmusp.relation.referenceLee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007eng
hcfmusp.relation.referenceMalphettes M, 2009, CLIN INFECT DIS, V49, P1329, DOI 10.1086/606059eng
hcfmusp.relation.referenceNiehues T, 2010, CLIN IMMUNOL, V135, P183, DOI 10.1016/j.clim.2010.01.013eng
hcfmusp.relation.referenceNotarangelo LD, 2016, NAT REV IMMUNOL, V16, P234, DOI 10.1038/nri.2016.28eng
hcfmusp.relation.referenceOhm-Laursen L, 2008, J CLIN IMMUNOL, V28, P588, DOI 10.1007/s10875-008-9210-7eng
hcfmusp.relation.referenceSchuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966eng
hcfmusp.relation.referenceThwaites DT, 2019, BLOOD, V133, P820, DOI 10.1182/blood-2018-07-866939eng
hcfmusp.relation.referenceWalter JE, 2015, J CLIN INVEST, V125, P4135, DOI 10.1172/JCI80477eng
dc.description.indexPubMedeng
hcfmusp.citation.scopus9-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICr
Instituto da Criança - HC/ICr

Artigos e Materiais de Revistas Científicas - LIM/36
LIM/36 - Laboratório de Pediatria Clínica

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_DORNA_Combined_Immunodeficiency_With_LateOnset_Progressive_Hypogammaglobulinemia_and_Normal_2019.PDFpublishedVersion (English)894.06 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.